A Study to Assess Anktiva in Patients With Long Covid
Phase 2
20
about 1 year
18–70
1 site in CA
About this study
This trial is testing the safety and tolerability of a treatment called Anktiva in people with Long COVID. Participants will receive up to two doses of Anktiva, along with follow-up exams and tests.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take N-803 (IL-15 Superagonist)
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Antineoplastic Agent [TC] (Cytokine Receptor Superfamily Interactions)
Primary: Incidence of grade 3 or higher TEAEs through 30 days post final study drug administration., Incidence of serious adverse events (SAEs) through 30 days post final study drug administration., Incidence of treatment emergent adverse events (TEAEs) through 30 days post final study drug administration.
Secondary: Change in other assessments (eg, EuroQoL Quality of Life) from baseline, intervention 2, FU2.3 (2 weeks after last NAI administration), FU2.5, and EOS., Change in patient-reported outcomes (PROs) PROMIS-29 score from Baseline to FU2.5 (45 days following last NAI administration).